secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0000950170-24-127058
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Cell Therapeutics Q3 2024 net loss $3.0M, revenue $3.8M; OpRegen gets RMAT designation
--------------------------------------------------------------------------------

- Net loss $3.0M ($0.02/sh) vs $7.1M ($0.04/sh) in Q3 2023; revenue $3.8M vs $1.2M.
- Cash $32.7M expected to fund operations into Q1 2026.
- OpRegen (RG6501) received RMAT designation from FDA for geographic atrophy secondary to AMD.
- OPC1 spinal cord injury study start-up activities ongoing; ReSonance preclinical results presented.
- Operating expenses $7.6M ($3.2M R&D, $4.4M G&A), down from $7.9M in Q3 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000095017024127058/0000950170-24-127058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000095017024127058/lctx-20241114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-127058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer